Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

invasive aspergillosis - Clinical Profile, Treatments & Trials | Kisho | Kisho

Rare Disease

invasive aspergillosis

MONDO:0000240

Find Clinical TrialsTrials

Overview

An aspergillosis that is a serious fungal infection of the lung with pneumonia caused by Aspergillus, which spreads to other parts of the body through bloodstream in patients with acute leukemia and recipients of tissue transplants. Clinical symptoms include pulmonary nodules and hemorrhage.

Treatments6 FDA approved

Clinical Trials9 registered · 3 recruiting

Diagnosis

Biomarker and diagnostic research for invasive aspergillosis has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

4 FDA-approved treatments are available for invasive aspergillosis, including POSACONAZOLE (NOXAFIL, approved 2021), ISAVUCONAZONIUM SULFATE (CRESEMBA, approved 2015), and VORICONAZOLE (VORICONAZOLE, approved 2017). An additional 5 compounds hold orphan drug designation.

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

9 clinical trials registered, 3 recruiting. Interventions under study include other interventions and drug therapy. Pipeline includes 1 PHASE4, 1 PHASE3. Research is sponsored by a mix of industry and academic institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT01386437](https://clinicaltrials.gov/study/NCT01386437)

Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 8:50 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

Questions for Your Care Team

→What are the benefits and potential side effects of NOXAFIL for managing invasive aspergillosis?
→Are any of the 9 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Brand Name	Generic Name	Sponsor	Designated	Exclusivity End	Designation Status
opelconazole	opelconazole	Pulmocide Inc.	2021	—	Designated
(1S,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E,31E)-33-(((2S,3S,4S,6R)-4-amino-3,5-dihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-1,3,4,7,9,11,17,37-octahydroxy-15,16,18,36-tetramethyl-14,39-dioxabicyclo[33. 3.1] nonatriaconta-19,21,23,25,27,29,31-heptaen-13-one	(1S,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E,31E)-33-(((2S,3S,4S,6R)-4-amino-3,5-dihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-1,3,4,7,9,11,17,37-octahydroxy-15,16,18,36-tetramethyl-14,39-dioxabicyclo[33. 3.1] nonatriaconta-19,21,23,25,27,29,31-heptaen-13-one	Biosergen AS	2021	—	Designated
olorofim	olorofim	F2G Limited	2020	—	Designated
fosmanogepix	fosmanogepix	Basilea Pharmaceutica Ltd, Allschwil	2016	—	Designated
Cyclo{-Asn-Leu-d-Phe-Al[(N5-acetyl-N5-hydroxy-Orn)-(N5-acetyl-N5-hydroxy-Orn)-(N5-hydroxy-Orn)]-} . Al(III)	Cyclo{-Asn-Leu-d-Phe-Al[(N5-acetyl-N5-hydroxy-Orn)-(N5-acetyl-N5-hydroxy-Orn)-(N5-hydroxy-Orn)]-} . Al(III)	Basilea Pharmaceutica International, Ltd., Allschwil	2015	—	Designated

Research Type	Count	% of Total
Research summaries	75	38%
Disease patterns and progression	33	17%
Patient case studies	30	15%
Testing and diagnosis research	20	10%
Laboratory research	20	10%
Clinical study results	17	9%
New treatment approaches	2	1%

Kisho

invasive aspergillosis

Overview

Diagnosis

Treatment

Approved Therapies

Research Landscape

Medical References

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials

Recent Publications

Latest News & Developments

Aspergillosis complicating idiopathic lung fibrosis: a multicentric series.

Rapid Diagnosis of Mucor and Aspergillus Co-Infection by Direct Microscopic Examination: A Case Report and Literature Review.

Peripheral T-cell lymphoma-NOS presenting with cavitary lung lesions mimicking invasive aspergillosis.

invasive aspergillosis

Overview

Diagnosis

Treatment

Approved Therapies

Research Landscape

Medical References

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials

Recent Publications

Latest News & Developments

Aspergillosis complicating idiopathic lung fibrosis: a multicentric series.

Rapid Diagnosis of Mucor and Aspergillus Co-Infection by Direct Microscopic Examination: A Case Report and Literature Review.

Peripheral T-cell lymphoma-NOS presenting with cavitary lung lesions mimicking invasive aspergillosis.